Hengrui Pharmaceuticals' GLP-1/GIP dual receptor agonist reupaglutide injection showed positive topline results in a pivotal trial in Chinese patients with inadequately controlled T2DM on oral drugs, with both dose groups meeting the noninferiority primary endpoint. The 4 mg group achieved a mean HbA1c reduction of 2.78% at week 36, an additional 0.49% mean reduction versus semaglutide injection 1 mg, with good overall tolerability and a safety profile similar to other GLP-1 agents.
Why it matters: The brief gives the HbA1c difference of reupaglutide 4 mg versus semaglutide 1 mg and safety data for comparison with existing GLP-1 drugs.
A team led by Professor Yanhong Deng at the Sixth Affiliated Hospital of Sun Yat-sen University published the PICC-2 randomized controlled trial in The Lancet Oncology. In patients with dMMR/MSI-H locally advanced colorectal cancer, adding the COX-2 inhibitor celecoxib to neoadjuvant toripalimab raised the pCR rate from 69% with monotherapy to 89% in the combination group, an absolute difference of 20 percentage points, with manageable safety.
Why it matters: The article reports pCR rates for both the combination and monotherapy groups, letting readers judge the incremental benefit of a COX-2 inhibitor in neoadjuvant immunotherapy for dMMR/MSI-H colorectal cancer.
The HAELO study, published in NEJM, reports clinical results of lonvoguran ziclumeran in hereditary angioedema using an in vivo CRISPR gene editing approach. DOI 10.1056/NEJMoa2600931.
Why it matters: The clinical readout in NEJM offers a reference for efficacy and durability of similar in vivo CRISPR gene editing strategies in related indications.
